Commentary

More on psilocybin

Author and Disclosure Information

 

I would like to remark on “Psychedelics for treating psychiatric disorders: Are they safe?” (Current Psychiatry, December 2022, p. 14-22, doi:10.12788/cp.0309), specifically “psilocybin use has been decriminalized … and some states (such as Oregon) have legalized it for therapeutic use.” I wanted to briefly clarify regarding the legal status of psilocybin.

The Oregon Psilocybin Services that will begin in 2023 are not specific to therapeutic use; this is a common misconception. These are specifically referred to as “psilocybin services” in the Oregon Administrative Rules (OAR), and psilocybin facilitators are required to limit their scope such that they are not practicing psychotherapy or other interventions, even if they do have a medical or psychotherapy background. The intention of the Oregon Psilocybin Services rollout was that these services would not be of the medical model. In the spirit of this, services do not require a medical diagnosis or referral, and services are not a medical or clinical treatment (OAR 333-333-5040). Additionally, services cannot be provided in a health care facility (OAR 441). Facilitators receive robust training as defined by Oregon law, and licensed facilitators provide this information during preparation for services. When discussing this model on a large public scale, I have noticed substantial misconceptions; it is imperative that we refer to these services as they are defined so that individuals with mental health conditions who seek them are aware that such services are different from psilocybin-assisted psychotherapy. Instead, Oregon Psilocybin Services might be better categorized as supported psilocybin use.

Recommended Reading

Medical student well-being during the COVID-19 pandemic
MDedge Psychiatry
Sleep complaints in major depression flag risk for other psychiatric disorders
MDedge Psychiatry
Postconcussion symptoms tied to high risk of depression
MDedge Psychiatry
Self-management app may boost quality of life
MDedge Psychiatry
Low serum LDH shows potential as depression biomarker
MDedge Psychiatry
Borderline patients have longer time to depression remission
MDedge Psychiatry
Anxiety sensitivity fuels depression in dissociative identity disorder
MDedge Psychiatry
Canadian Task Force recommendation on screening for postpartum depression misses the mark
MDedge Psychiatry
Geriatrician advises on use of vitamin D supplementation, lecanemab, and texting for her patients
MDedge Psychiatry
Guidelines recommend CBT alone for mild acute depression, more options for more severe cases
MDedge Psychiatry